PMV Pharmaceuticals, Inc. (PMVP): R&D Expense
$69.88M
Year ended 2025-12-31
$64.04M
Trailing 12 months to 2026-06-30
+10.4%
3-year compound annual growth
+23.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $69.88M | +19.4% | 2026-03-06, From 2025-01-01 |
| 2024-12-31 | $58.53M | +4.7% | 2026-03-06, From 2024-01-01 |
| 2023-12-31 | $55.88M | +7.5% | 2026-03-06, From 2023-01-01 |
| 2022-12-31 | $51.99M | +42.5% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $36.49M | +52.5% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $23.93M | +15.3% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $20.76M | +49.9% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $13.85M | n/a | 2021-03-03, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $69.88M | +19.4% |
| Sagimet Biosciences Inc. (SGMT) | 2025-12-31 | $39.05M | +1.6% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $48.94M | +181.8% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $38.20M | -1.6% |
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $26.59M | -61.8% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $12.82M | +207.5% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $23.52M | -75.4% |
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $18.11M | +26.1% |
Compare PMVP, SGMT, AVTX, AARD side by side · Screen every company in Pharmaceutical Preparations ↗